Viewing Study NCT06945705


Ignite Creation Date: 2025-12-25 @ 3:11 AM
Ignite Modification Date: 2026-01-01 @ 1:57 AM
Study NCT ID: NCT06945705
Status: RECRUITING
Last Update Posted: 2025-04-25
First Post: 2025-03-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
Sponsor: Henan Cancer Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module